Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

Sham-Controlled Trial, and More, Bolster Pulsed-Field Ablation for AF

News Conference News AHA 2025

Sham-Controlled Trial, and More, Bolster Pulsed-Field Ablation for AF

November 17, 2025

LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF

News Conference News AHA 2025

LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF

November 09, 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

News Conference News AHA 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

November 09, 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

November 08, 2025

What’s Going to Be Hot at AHA 2025?

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

Infections No More Likely With Reconditioned Versus New Pacemakers

News Conference News AHA 2024

Infections No More Likely With Reconditioned Versus New Pacemakers

Yael L. Maxwell

November 22, 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

News Conference News AHA 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

November 18, 2024

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

News Conference News AHA 2024

ENBALV: Edoxaban Matches Warfarin After Bioprosthetic Valve Surgery

Yael L. Maxwell

November 17, 2024

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

News Conference News AHA 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

November 12, 2023

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

News Conference News AHA 2022

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

Michael O'Riordan

November 10, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

GIRAF: Cognitive Outcomes Similar With Dabigatran, Warfarin in Older AF Patients

News Conference News AHA 2021

GIRAF: Cognitive Outcomes Similar With Dabigatran, Warfarin in Older AF Patients

November 14, 2021

One in Five Patients Admitted With COVID-19 Die in the Hospital

News Conference News AHA 2020

One in Five Patients Admitted With COVID-19 Die in the Hospital

Michael O'Riordan

November 20, 2020

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

News Conference News AHA 2020

Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib

November 14, 2020

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

News Conference News AHA 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

November 11, 2018

‘Acceptable Safety’ for LAA Closure Seen in a Real-World, All-Comers Registry

News Conference News AHA 2017

‘Acceptable Safety’ for LAA Closure Seen in a Real-World, All-Comers Registry

November 22, 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

November 16, 2017

Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma

News Conference News AHA 2017

Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma

November 15, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.